Company Overview
XOMA Royalty Corporation operates as a biotech royalty aggregator with a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates. This business model places the company within the Healthcare sector, specifically the Biotechnology industry, where it functions to monetize intellectual property rather than directly developing or manufacturing pharmaceutical goods. The company maintains a workforce of 14 employees, generating Total Revenue of $52.15M over the trailing twelve months. These financial figures and the current market capitalization status reflect a specialized niche position in the biotechnology landscape, where the company leverages its asset base to generate income streams without the capital expenditure burden of traditional drug development.
Financial Health
Over the trailing twelve months, the company reported Revenue of $52.15M and Net Income of $18.52M, while EBITDA stands at $14.36M. The significant gap between the reported Net Income and EBITDA reveals a substantial non-operating or non-cash expense structure, likely driven by interest costs on debt or other adjustments not included in operating earnings. However, the company reports Free Cash Flow of $-14,235,375, indicating a current burn rate that limits immediate financial flexibility despite strong accounting profits. Profitability is underscored by a Gross Margin of 96.7%, an Operating Margin of 15.9%, and a Profit Margin of 60.8%, demonstrating exceptional efficiency in converting revenue into profit before accounting for capital structure costs. Regarding liquidity and leverage, the company holds Cash of $83.29M against a Debt load of $131.56M, resulting in a Debt to Equity ratio of 126.54, which characterizes a highly leveraged balance sheet. This leverage is partially mitigated by a Current Ratio of 3.37, which indicates a robust short-term liquidity position capable of covering current liabilities many times over. Return metrics show a Return on Equity of 34.1% and a Return on Assets of 2.9%, suggesting that while equity holders are generating high returns on their investment, the asset base as a whole is yielding lower returns, a dynamic often seen in capital-intensive or highly leveraged royalty models.
Valuation Assessment
The company trades at a Trailing P/E ratio of 25.58, whereas the Forward P/E is not available, implying that market expectations for future earnings growth relative to current valuation are not currently quantifiable through standard forward metrics. The Price to Book ratio is 3.62, indicating that the market values the company at a significant premium over its net asset book value, likely reflecting the high value placed on its intellectual property portfolio. While the Price to Sales ratio is not available, the EV/EBITDA multiple is 25.83, suggesting that the enterprise value is priced high relative to its operating earnings before interest, taxes, depreciation, and amortization. Regarding trading range, the 52-Week High is $25.76 and the 52-Week Low is $23.32, meaning the stock is currently trading within a relatively narrow band near the upper end of its annual range. The Beta of 0.83 indicates that the stock's price volatility is lower than the broader market, suggesting it may be less sensitive to general market fluctuations compared to the S&P 500.
Growth & Income
Revenue Growth over the last year is 57.9%, while Earnings Growth is not available for comparison, preventing a direct calculation of whether earnings are growing faster or slower than revenue at this specific moment. The company offers a Dividend Yield of 8.2%, but the Payout Ratio is not available, which prevents a definitive assessment of the sustainability of this payout relative to reported earnings per share. Given the lack of a Payout Ratio, the high dividend yield must be analyzed in the context of the company's ability to maintain payments despite the negative free cash flow and high debt levels. Overall, the company presents a profile characterized by strong revenue expansion and a high dividend yield, though the absence of forward P/E and earnings growth data limits a complete picture of future growth trajectories.